Journal Home
Search for

Volume 184, Issue 1, Pages 87-91 (July 2010)


View previous. 22 of 101 View next.

Surgical Margin Status After Robot Assisted Radical Cystectomy: Results From the International Robotic Cystectomy Consortium

Nicholas J. Hellenthala, Abid Hussaina, Paul E. Andrewsb, Paul Carpentierc, Erik Castleb, Prokar Dasguptad, Jihad Kaouko, Shamim Khand, Adam Kibelf, Hyung Kima, Murugesan Manoharang, Mani Menonh, Alex Mottriec, David Ornsteini, Joan Palouh, James Peabodyk, Raj Pruthij, Lee Richstonel, Francis Schannem, Hans Strickerh, Raju Thomase, Peter Wiklundn, Greg Wildinga, Khurshid A. GuruaCorresponding Author Informationemail address

Received 2 December 2009 published online 17 May 2010.

Purpose

Positive surgical margins at radical cystectomy confer a poor prognosis. We evaluated the incidence and predictors of positive surgical margins in patients who underwent robot assisted radical cystectomy for bladder cancer.

Materials and Methods

Using the International Robotic Cystectomy Consortium database we identified 513 patients who underwent robot assisted radical cystectomy, as done by a total of 22 surgeons at 15 institutions from 2003 to 2009. After stratification by age group, gender, pathological T stage, nodal status, sequential case number and institutional volume logistic regression was used to correlate variables with the likelihood of a positive surgical margin.

Results

Of the 513 patients 35 (6.8%) had a positive surgical margin. Increasing 10-year age group, lymph node positivity and higher pathological T stage were significantly associated with an increased likelihood of a positive margin (p = 0.010, <0.001 and p <0.001, respectively). Gender, sequential case number and institutional volume were not significantly associated with margin positivity. The rate of margin positive disease at cystectomy was 1.5% for pT2 or less, 8.8% for pT3 and 39% for pT4 disease.

Conclusions

Positive surgical margin rates at robot assisted radical cystectomy for advanced bladder cancer were similar to those in open cystectomy series in a large, multi-institutional, prospective cohort. Sequential case number, a surrogate for the learning curve and institutional volume were not significantly associated with positive margins at robot assisted radical cystectomy.

Article Outline

Abstract

Materials and Methods

Patients and Databases

Population

Statistical Analysis

Results

Discussion

Conclusions

Appendix

References

Copyright

Radical cystectomy with or without neoadjuvant chemotherapy remains the gold standard treatment for invasive urothelial carcinoma of the bladder. The 5-year survival rate is 60% to 67% in patients with T2 disease and metastatic failure develops in 20% to 30% with locally advanced disease.1, 2 Tumor stage, lymph node metastasis and particularly soft tissue surgical margin status at cystectomy have been cited as critical to disease specific and overall survival.

Patients with positive soft tissue surgical margins have a poor prognosis with a 5-year local recurrence rate of up to 21% and less than 20-month median survival in recent studies.3 Large open RC series at established academic centers have traditionally cited 1% to 10% positive surgical margin rates.3, 4, 5 These rates have set the standard to which margin rates in alternative forms of cystectomy are compared.

Robotic surgery has been gaining acceptance in the urological community, especially for localized prostate cancer.6 Literature suggests that robot assisted radical prostatectomy oncological outcomes at 5 years are similar to those of open radical prostatectomy but the former may allow more rapid convalescence.7 However, in patients with invasive urothelial carcinoma there are sparse data on oncological outcomes after RARC. This lack of data along with the fact that invasive bladder cancer is much less prevalent in the United States has limited the integration of robotic surgery into the performance of RC. Particular concerns have been raised over surgical margin status, pelvic lymph node dissection adequacy and learning curves that may be associated with the operation.

With this in mind we queried a multi-institutional, prospectively maintained international database to identify the rate of positive soft tissue surgical margins in patients who underwent RARC for urothelial carcinoma. We assessed the influence of tumor stage, surgeon volume and institutional experience on the positive margin rate.

Materials and Methods 

return to Article Outline

Patients and Databases 

The prospectively maintained IRCC database is an effort of a mixture of academic and private centers in Buffalo, New York; Scottsdale, Arizona; New Orleans, Louisiana; London, United Kingdom; St. Louis, Missouri; Miami, Florida; Detroit, Michigan; Aalst, Belgium; Naples, Florida; Chapel Hill, North Carolina; Barcelona, Spain; Long Island, New York; Wilmington, Delaware; Cleveland, Ohio; and Stockholm, Sweden comprising patients treated with RARC for clinically localized urothelial carcinoma from 2003 to 2009. Patients were divided into 2 groups for further analysis, including those with positive or negative surgical margins. All pathological specimens were reviewed by a trained institutional pathologist using the American Joint Committee on Cancer TNM staging system relevant to time of diagnosis.

Population 

Clinical and pathological data were available on 513 patients who underwent RARC for urothelial carcinoma, as done by 1 of 22 surgeons at the 15 participating institutions. Of these patients 35 (6.8%) had a positive surgical margin on pathological examination. Patient age was 34 to 90 years (mean 68) and 106 (21%) were women.

Clinical features evaluated were age, gender, pathological T stage, lymph node status, sequential case number and institutional volume. All patients were included in analysis since surgical margin status was available in all at the time of review.

Statistical Analysis 

Primary outcome measures were the incidence and predictors of positive surgical margins in patients. Cohorts were defined by gender (male or female), age group (60 years or less, 61 to 70, 71 to 80 and 81 or greater), pathological T stage (pT2 or less, pT3 and pT4), lymph node status (negative or positive), sequential case number (cases 1 to 10, 11 to 20, 21 to 40, and 41 and greater) and total institutional volume (50 or fewer cases, or greater than 50). Logistic regression analysis was used to examine relationships between the various cohorts and the likelihood of a positive surgical margin. Clinical variables significantly associated with the likelihood of a positive margin on univariate analysis were included in the multivariate model. The predicted probability of a positive surgical margin based on institutional case volume was generated using post logistic regression estimation analysis. Statistical analysis was done with Stata®, version 10.0.

Results 

return to Article Outline

Of 513 patients 35 (6.8%) had a positive surgical margin. Surgical margin status was significantly associated with increasing 10-year age group, higher pathological T stage and positive lymph nodes (table 1). Patients 70 to 80 years old and those 81 years old or older were 6.41 and 8.93 times more likely to have a positive margin on pathological review than patients 60 years old or younger (p = 0.014 and 0.004, respectively). Those with pT3 and pT4 disease were 6.28 and 41.4 times more likely to have positive surgical margins than those with pT2 or less disease (p = 0.001 and <0.001, respectively). Those with disease metastatic to lymph nodes were 6.63 times more likely to have a positive margin than those with negative lymph nodes (p <0.001).

Table 1.

Patients with positive surgical margins at RC

No. Margin Neg
No. Margin Pos
Total No.
OR (95% CI)
p Value
Age group:
60 or Less1262128Referent 1.0
61–7014591543.91 (0.83–18.43)0.085
71–80167171846.41 (1.46–28.26)0.014
81 or Greater407478.93 (2.20–55.2)0.004
Gender:
M37928407Referent 1.00.920
F9971060.96 (0.41–2.26)
Stage:
T2 or less3225327Referent 1.0
T3123121356.28 (2.16–18.20)0.001
T428184641.4 (14.29–119.90)<0.001
Nodal status:
Neg39815413Referent 1.0
Pos80201006.63 (3.26–13.51)<0.001
Sequential case No.:
10 or Less11212124Referent 1.0
11–209891070.93 (0.38–2.31)0.882
21–4012361290.50 (0.18–1.36)0.174
41 or Greater13581430.60 (0.24–1.52)0.284
No. institutional cases:
50 or Less23619255Referent 1.0
Greater than 50242162580.82 (0.41–1.64)0.575
Totals47835513

Statistical significance was achieved when the 95% CI did not exceed 1.0.

On multivariate analysis age group and pathological T stage remained significantly associated with a positive margin. Tumor T stage most significantly correlated with a positive margin. With all other variables remaining constant for each increase in pathological T stage above pT2 there was a 5 times higher chance (95% CI 3.00–9.57) of a positive surgical margin (p <0.001). With all other variables remaining constant each 10-year age increase above age 61 years also carried a 1.81 times higher chance (95% CI 1.15–2.85) of a positive surgical margin (p = 0.010).

Gender, sequential case number and total institutional volume were not significantly associated with a positive surgical margin. The predicted probability of a positive surgical margin remained constant at approximately 10% independent of overall institutional volume when using actual and linear fit models (see figure).


View full-size image.

Probability of positive surgical margin based on number of cases per institution using logistic regression for actual values and linear fit of logistic regression for linear fit correlation.


The proportion of patients in each stage group was similar in the early and later sequential case groups in terms of tumor stage at RARC (table 2). The incidence of high stage (pT3 or greater) disease was 30% to 38% independent of sequential case volume.

Table 2.

Stage based on surgeon sequential case number

Sequential Case No.
No. T2 or Less (%)
No. T3 (%)
No. T4 (%)
Total No.
10 or Less84 (62)39 (29)13 (9)136
11–2067 (62)23 (21)18 (17)108
21–4090 (70)32 (25)7 (5)129
41 or Greater92 (64)42 (29)9 (7)143
Totals333 (63)136 (27)47 (10)516

Discussion 

return to Article Outline

Positive soft tissue surgical margins at RC are associated with progression to metastatic disease and dismal disease specific survival in patients with invasive urothelial carcinoma.3, 8, 9 The data show an overall 7% positive soft tissue surgical margin rate, comparable to the 1% to 10% in large open cystectomy series.3, 4, 5 The data are also in line with small laparoscopic and robotic cystectomy series showing a 1% to 6% positive margin rate.10, 11, 12 However, previously reported minimally invasive studies were low volume (typically less than 50 patients), single institutional experiences. In this large, multi-institutional setting the overall positive surgical margin rate approximated those in open series in a multi-institutional setting.

In our study patients were chosen based on an initial diagnosis of clinically nonmetastatic invasive urothelial carcinoma. No attempt was made to operate only in those with a minimal tumor burden. Of the 513 patients 181 (35%) had extravesical disease on final pathological examination, similar to the 30% rate of extravesical disease in larger open series.13

Pathological tumor stage and lymph node metastasis were significantly associated with positive surgical margins. Patients with pT3 or pT4 disease were 6 and 40 times more likely, respectively, to have a positive margin at RARC than those with pT2 or less disease. Likewise, those with lymph node metastasis were 7 times more likely to have a positive surgical margin. A recent series from Memorial Sloan-Kettering Cancer Center evaluating survival in the setting of positive surgical margins after RC also showed that pathological stage and lymph node metastasis are associated with positive margins.3 In this study of 1,589 patients the overall positive margin rate was 4.2%. Further analysis showed no positive margins in patients with organ confined disease and a 9% positive margin rate in those with extravesical disease. In this series 30 of 181 patients (16.6%) with extravesical (pT2 or greater) disease had a positive surgical margin, in line with the standards of the Bladder Cancer Collaborative Group, which cited a 15% or less positive margin rate as a goal at high volume centers.14 Upon further breakdown the positive margin rate was 8.8% in patients with pT3 disease (12 of 135) and 39% in those with pT4 disease (18 of 46). However, the margin rate in IRCC participants with extravesical (pT3 or greater) disease ranged from no positive margins in as many as 11 to 50%, representing 5 in a group in which 10 had pT3 or greater disease.

On a smaller scale advanced patient age was associated with an increased likelihood of a positive surgical margin. Those who were 71 to 80 years old and those who were 81 years old or older were 6 and 9 times more likely, respectively, to have a positive surgical margin than those 60 years old or younger. These data are similar to those in a prior collaborative group study showing that patient age correlated with surgical margin status and the number of lymph nodes retrieved at open RC.5 Increased positive margin rates in our series are explained largely by tumor stage. Of 231 patients 92 (43%) who were 71 years old or older presented with pT3 or higher disease while only 32 of 128 (27%) 60 years old or younger presented with extravesical disease (data not shown). Thus, while the positive margin rates were higher, older patients in our cohort often presented with more advanced disease.

Previous studies show that a learning curve may exist when incorporating robot assisted surgery into practice, specifically in regard to time and surgical margin rates for robot assisted radical prostatectomy.15, 16 Similarly incorporating RARC into practice may ultimately come with an unacceptable surgeon learning curve, particularly as it relates to surgical margin status. In this study sequential case volume served as a surrogate for a learning curve and no significant difference in surgical margin status was associated with cases 11 to 20, 21 to 40 or 41 and higher compared to the initial 10 cases. Institutional positive margin rates ranged from 0% in as many as 91 patients at 1 institution to 30% at 1 institution with 20 patients. When we looked at these 2 institutions, the institution with the 0% margin rate only had 3 patients (3%) with pathological T3 or T4 disease while the institution with the 30% positive margin rate had 15 (75%) with pT3 or T4 disease. However, overall surgical margin status was not significantly associated with institutional volume. Positive margin rates at centers with more than 50 cases were no different than those at centers with 50 or fewer.

Generally IRCC comprises a relatively experienced group of robotic surgeons with an average of 120 (range 0 to 400) robot assisted radical prostatectomies done before performing RARC. While prior robotic experience may have a role in the essentially equivocal positive margin rate, one must also evaluate large open cystectomy series in similar fashion. Most of the published literature has also been from high volume, experienced open surgeons.

IRCC surgeons did not appear to discriminate in terms of stage selection. About 30% to 40% of cases were high stage (pT3 or greater), comparable to the University of Southern California open cystectomy experience in which 29% were pT3 or greater.13 High stage cases were also relatively equally disbursed among the sequential case numbers. Of the 136 cases in the initial 10-case group 52 (38%) were high stage, similar to the 51 of 143 high stage cases (36%) in a group further along the learning curve (cases 41 or greater). Some may argue that simple cases should be selected early in the RARC experience but differences in the margin rate were not attributable to case number.

This study has several limitations. Pathological review of surgical specimens was not centralized, which may have introduced some variation in interpreting surgical margin status. Despite being what is to our knowledge the largest report of RARC experience to date the cohort comprised fewer patients than contemporary open series. Given more time, greater experience may the affect positive margin rate. Finally, as in any large database, there is the possibility of data entry miscoding. However, this potential error should be nonselective over the cohort analyzed and in effect negate overt bias.

Conclusions 

return to Article Outline

The positive surgical margin rate at RARC for advanced bladder cancer in a large, multi-institutional, prospective cohort was approximately 7%, similar to open cystectomy series. As in open series, increasing age, pathological T stage and lymph node metastasis appear to be associated with an increased likelihood of a positive margin. Case number, which is a surrogate for a learning curve and institutional volume, was not associated with a positive margin.

Appendix 

return to Article Outline

Financial interest and/or other relationship with Intuitive Surgical (JK, JP), Specrum, Sanofi-Aventis and Envisioneering (AK), Pfizer (HK), Correlogics (DO), GTx (RP), Gulf South Lithotripsy, Intuitive Surgical, Olympus and The Journal of Urology® (RT), and Intuitive Surgical and Simulated Logical Systems (KAG).

References 

return to Article Outline

1. 1Herr HW, Dotan Z, Donat SM, et al. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007;177:437. Abstract | Full Text | Full-Text PDF (151 KB) | CrossRef

2. 2Montie JE. Against bladder sparing: surgery. J Urol. 1999;162:452. Abstract | Full Text | Full-Text PDF (580 KB) | CrossRef

3. 3Dotan ZA, Kavanagh K, Yossepowitch O, et al. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J Urol. 2007;178:2308. Abstract | Full Text | Full-Text PDF (257 KB) | CrossRef

4. 4Cheng L, Weaver AL, Leibovich BC, et al. Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer. 2000;88:2326.

5. 5Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22:2781. CrossRef

6. 6Guru KA, Hussain A, Chandrasekhar R, et al. Current status of robot-assisted surgery in urology: a multi-national survey of 297 urologic surgeons. Can J Urol. 2009;16:4736.

7. 7Badani KK, Kaul S, Menon M. Evolution of robotic radical prostatectomy: assessment after 2766 procedures. Cancer. 2007;110:1951.

8. 8Canter D, Guzzo TJ, Resnick MJ, et al. A thorough pelvic lymph node dissection in presence of positive margins associated with better clinical outcomes in radical cystectomy patients. Urology. 2009;74:161. Abstract | Full Text | Full-Text PDF (205 KB) | CrossRef

9. 9Hadjizacharia P, Stein JP, Cai J, et al. The impact of positive soft tissue surgical margins following radical cystectomy for high-grade, invasive bladder cancer. World J Urol. 2009;27:33. CrossRef

10. 10Haber GP, Gill IS. Laparoscopic radical cystectomy for cancer: oncological outcomes at up to 5 years. BJU Int. 2007;100:137. MEDLINE | CrossRef

11. 11Pruthi RS, Wallen EM. Is robotic radical cystectomy an appropriate treatment for bladder cancer? (Short-term oncologic and clinical follow-up in 50 consecutive patients). Urology. 2008;72:617. Abstract | Full Text | Full-Text PDF (73 KB) | CrossRef

12. 12Wang GJ, Barocas DA, Raman JD, et al. Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy. BJU Int. 2008;101:89.

13. 13Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666.

14. 14Herr H, Lee C, Chang S, et al. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. J Urol. 2004;171:1823. Abstract | Full Text | Full-Text PDF (76 KB) | CrossRef

15. 15Ahlering TE, Skarecky D, Lee D, et al. Successful transfer of open surgical skills to a laparoscopic environment using a robotic interface: initial experience with laparoscopic radical prostatectomy. J Urol. 2003;170:1738. Abstract | Full Text | Full-Text PDF (69 KB) | CrossRef

16. 16Atug F, Castle EP, Srivastav SK, et al. Positive surgical margins in robotic-assisted radical prostatectomy: impact of learning curve on oncologic outcomes. Eur Urol. 2006;49:866. Abstract | Full Text | Full-Text PDF (113 KB) | CrossRef

a Department of Urologic Oncology, Roswell Park Cancer Institute, Buffalo, New York

b Department of Urologic Oncology, Mayo Clinic, Scottsdale, Arizona

c Department of Urologic Oncology, Onze-Lieve-Vrouw Ziekenhuis, Aalst, Belgium

d Department of Urologic Oncology, Guy's Hospital, London, United Kingdom

e Department of Urologic Oncology, Tulane University, New Orleans, Louisiana

f Department of Urologic Oncology, Washington University, St. Louis, Missouri

g Department of Urologic Oncology, University of Miami, Miami, Florida

h Department of Urologic Oncology, Henry Ford Health System, Detroit, Michigan

i Department of Urologic Oncology, 21st Century Oncology, Naples, Florida

j Department of Urologic Oncology, University of North Carolina, Chapel Hill, North Carolina

k Department of Urologic Oncology, Fundaçio Puigvert, Barcelona, Spain

l Department of Urologic Oncology, Arthur Smith Institute for Urology, Long Island, New York

m Department of Urologic Oncology, Urologic Surgical Associates of Delaware, Wilmington, Delaware

n Department of Urologic Oncology, Karolinska University, Stockholm, Sweden

o Department of Urologic Oncology, Cleveland Clinic Foundation, Cleveland, Ohio

Corresponding Author InformationCorrespondence and requests for reprints: Department of Urologic Oncology, Roswell Park Cancer Institute, Elm and Carlton Sts., Buffalo, New York 14263 (telephone: 716-845-3389; FAX: 716-845-3300)

 Study received institutional review board approval.

PII: S0022-5347(10)03014-4

doi:10.1016/j.juro.2010.03.037


View previous. 22 of 101 View next.